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Abstract 28 
 29 
The purpose of this study was to compare the effects of L-citrulline (CIT) and L-30 
arginine (ARG) supplementation on nitric oxide (NO) biomarkers, pulmonary O2 31 
uptake ( O2) kinetics and exercise performance.  In a randomised, placebo-controlled, 32 
cross-over study, ten healthy adult males completed moderate- and severe-intensity 33 
cycling exercise on days 6 and 7 of a 7 day supplementation period with placebo 34 
(PLA), 6 g·day-1 of ARG and 6 g·day-1 of CIT.  Compared to PLA, plasma [ARG] 35 
was increased by a similar magnitude with ARG and CIT supplementation, but 36 
plasma [CIT] was only increased (P<0.001) with CIT supplementation.  Plasma nitrite 37 
concentration ([NO2-]) was increased with ARG (P<0.05), and tended to increase with 38 
CIT (P=0.08), compared to PLA (PLA: 83 ± 25, ARG: 106 ± 41, CIT: 100 ± 38 nM); 39 
however, mean arterial blood pressure was only lower (P<0.05) after CIT 40 
supplementation.  The steady state O2 amplitude during moderate-intensity cycle 41 
exercise was not significantly different between supplements, but CIT speeded overall 42 
O2 kinetics (PLA: 59 ± 8, CIT: 53 ± 5 s; P<0.05) during severe-intensity exercise, 43 
improved tolerance to severe-intensity exercise (PLA: 589 ± 101, CIT: 661 ± 107 s) 44 
and increased the total amount of work completed in the exercise performance test 45 
(PLA: 123 ± 18, CIT: 125 ± 19 kJ; P<0.05).  These variables were not altered by 46 
ARG supplementation (P>0.05).  In conclusion, these results suggest that short-term 47 
CIT, but not ARG, supplementation can improve blood pressure, O2 kinetics and 48 
exercise performance in healthy adults.     49 
 50 
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Introduction 62 
 63 
The multifaceted physiological signalling molecule, nitric oxide (NO), can be 64 
synthesised endogenously through the nitrate-nitrite-NO pathway (37) and through 65 
the five-electron oxidation of L-arginine (ARG) in a reaction catalyzed by the nitric 66 
oxide synthase (NOS) enzymes (55).  While studies have shown that dietary nitrate 67 
supplementation can increase NO biomarkers, reduce blood pressure and improve 68 
exercise economy/efficiency and exercise tolerance in healthy adults (see 4 for 69 
review), the extent to which these variables are impacted by dietary ARG 70 
supplementation is less clear (see 1 for review).  However, when ARG treatment 71 
increases NO biomarkers, exercise economy and exercise performance are improved 72 
(5, 52), whereas exercise economy and exercise performance are not improved when 73 
ARG treatment does not influence NO synthesis (9, 31, 35).  Therefore, while there is 74 
some evidence to suggest that ARG treatment might improve physiological responses 75 
in conjunction with elevated NO synthesis, an optimal ARG administration procedure 76 
to enhance NO synthesis and associated physiological responses has yet to be 77 
established.     78 
 79 
A significant obstacle to increasing ARG delivery to NOS via ARG supplementation 80 
is that orally ingested ARG is subjected to a number of presystemic and systemic 81 
elimination processes.  Approximately 40% of ingested oral ARG is catabolised by 82 
intestinal bacteria and arginases on the first pass (13, 67), with a further 10-15% of 83 
systemic ARG extracted and metabolized by the liver (13, 44, 48, 59, 71).  While both 84 
acute (57) and short term (34) ARG ingestion have been shown to increase plasma 85 
[ARG], the intracellular utilisation of this additional substrate by NOS might be 86 
restricted by the competition between ARG, asymmetric dimethylarginine (ADMA) 87 
and other ARG analogues for the transporter, y+ carrier hCAT-2B (14).  This 88 
regulation of ARG transport and metabolism could account for the finding that only ~ 89 
1% of an oral ARG dose is utilised as substrate by NOS (11).  Based on these 90 
restrictions, it appears that oral ARG supplementation might not be the optimal 91 
method to stimulate NO production through the NOS pathway.   92 
 93 
L-citrulline (CIT) is co-produced with NO as an end product of NOS activity.  It is 94 
well documented that NOS-derived CIT is efficiently recycled into ARG for 95 
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subsequent NO production through the CIT-NO cycle (24).  Therefore, exogenous 96 
CIT administration might represent an attractive alternative to increase ARG 97 
provision to NOS.  An advantage of oral CIT treatment is that, unlike ARG, 98 
catabolism of this amino acid in the intestines is limited since CIT is not metabolized 99 
by arginases and bacteria, and the activity of arginoinosuccinate synthase, the enzyme 100 
that initiates CIT metabolism, is low in enterocytes (68).  Moreover, and also in 101 
contrast to ARG, CIT is not extracted from the systemic circulation for clearance by 102 
the liver (59, 65).  Consequently, the majority of an oral CIT bolus passes into the 103 
systemic circulation (43).  CIT is then extracted by the kidneys to be converted, in 104 
sequence, to argininosuccinate and ARG by the enzymes arginoinosuccinate synthase 105 
and arginoinosuccinate lyase, respectively (15, 24, 59, 65, 70).  Synthesis of ARG 106 
from CIT is prevalent in other tissues (15, 23, 70) and this process is facilitated since 107 
CIT does not compete with ADMA for cell transport (50, 69).  Importantly, it has 108 
been shown that oral CIT supplementation is more effective at increasing the 109 
circulating (32, 57, 53, 62) and tissue (63) [ARG] compared to an equivalent dose of 110 
ARG, and that CIT supplementation can increase NOS activation (63) and NO 111 
biomarkers (46, 53).  Therefore, these findings suggest that CIT might serve as an 112 
important precursor for NO production.    113 
 114 
Chronic supplementation with L-citrulline malate has been shown to enhance skeletal 115 
muscle power output in concert with a greater oxidative energy turnover and a lower 116 
power/pH ratio (7), and a lower ATP cost of muscle force production (19).  These 117 
data suggest that short-term L-citrulline malate supplementation might improve 118 
skeletal muscle metabolism and/or contractile efficiency, which would be expected to 119 
predispose to greater fatigue resistance.  However, since these experiments 120 
administered CIT as L-citrulline malate, and since malate is an important tricarboxylic 121 
acid cycle intermediate that might itself influence muscle function (61), it is unclear 122 
whether these beneficial effects can be attributed to CIT, per se.  Hickner et al. (26) 123 
reported compromised endurance performance in concert with a lower plasma 124 
concentration of [nitrate] + [nitrite] ([NOx]) in humans following the acute ingestion 125 
of pure CIT.  In contrast, seven days of supplementation with pure CIT has been 126 
shown to improve endurance exercise performance in mice (55).  While these data 127 
suggest that chronic CIT supplementation has greater potential to improve endurance 128 
exercise performance than acute CIT ingestion, this has yet to be investigated in 129 
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humans.  Moreover, since NO biomarkers have not been assessed in studies reporting 130 
positive effects of CIT on muscle function and metabolism (7, 19, 56), it is unclear 131 
whether these improvements are linked to an increase in NOS-derived NO.  It is also 132 
unclear whether the improvements in muscle metabolism and performance with 133 
chronic CIT (7, 19, 56) are linked to improved oxygen uptake ( O2) kinetics.  134 
Therefore, further research is required to assess whether short-term oral CIT can 135 
influence NO synthesis and exercise performance, and the underlying mechanisms for 136 
any performance gains with CIT. 137 
 138 
The purpose of this study was to investigate the effects of short-term ARG and CIT 139 
supplementation on plasma [ARG], [CIT] and [NO2-], a sensitive marker of NOS 140 
activity (34), as well as blood pressure, O2 kinetics and exercise performance 141 
compared to a taste- and energy-matched placebo.  We hypothesised that, when 142 
compared to placebo: 1) plasma [ARG] would be increased to a greater extent with 143 
ARG than CIT; and 2) that CIT but not ARG would elevate plasma [NO2-], reduce 144 
blood pressure and improve O2 kinetics, cycling efficiency and exercise 145 
performance.          146 
 147 
Methods 148 
 149 
Subjects 150 
Ten healthy, recreationally-active males (mean ± SD, age 19 ± 1 yr, height 1.80 ± 0.08 151 
m, body mass 79 ± 11 kg) volunteered to participate in this study.  None of the 152 
subjects were tobacco smokers or users of dietary supplements.  The procedures 153 
employed in this study were approved by the Institutional Research Ethics Committee.  154 
All subjects gave their written informed consent prior to the commencement of the 155 
study, after the experimental procedures, associated risks, and potential benefits of 156 
participation had been explained.  Subjects were instructed to arrive at the laboratory 157 
in a rested and fully hydrated state, at least 3 h postprandial, and to avoid strenuous 158 
exercise in the 24 h preceding each testing session.  Each subject was also asked to 159 
refrain from caffeine and alcohol 6 and 24 h before each test, respectively.  All tests 160 
were performed at the same time of day (± 2 hours). 161 
 162 
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Experimental Design 163 
Subjects were required to report to the laboratory on eight occasions over 6-7 weeks 164 
to complete the experimental testing.  On the first visit to the laboratory subjects 165 
completed a ramp incremental exercise test for determination of the gas exchange 166 
threshold (GET) and the peak oxygen uptake ( O2peak).  Subjects were familiarized 167 
with the two exercise performance tests employed in this study during the second 168 
laboratory testing session.  After these preliminary exercise tests, subjects returned to 169 
the laboratory on days six and seven of 7-day supplementation periods with placebo 170 
(PLA), L-arginine (ARG) and L-citrulline (CIT) to complete the experimental testing.  171 
During these tests, resting blood pressure, pulmonary O2 kinetics, muscle 172 
oxygenation and exercise performance were assessed and a resting venous blood 173 
sample was obtained.  The supplements were administered orally in a randomized 174 
order as part of a double blind, cross-over experimental design.  Each 175 
supplementation period was separated by 7-10 days of washout.  Subjects were 176 
provided with a food diary for the first supplementation intervention and were 177 
instructed to replicate their diet over subsequent supplementation periods. 178 
 179 
Incremental Test 180 
During the first laboratory visit subjects completed a ramp incremental cycle test on 181 
an electronically-braked cycle ergometer (Lode Excalibur Sport, Groningen, the 182 
Netherlands).  Initially, subjects performed 3 min of baseline cycling at 0 W, after 183 
which the work rate was increased by 30 W/min until the limit of tolerance.  The 184 
subjects cycled at a self-selected pedal rate (70-90 rpm) and this pedal rate along with 185 
saddle and handle bar height and configuration was recorded and reproduced in 186 
subsequent tests.  Breath-by-breath pulmonary gas-exchange data were collected 187 
continuously during the incremental tests and averaged over consecutive 10-s periods.  188 
The o2max was taken as the highest 30-s mean value attained prior to the subject’s 189 
volitional exhaustion in the test.  The GET was determined from a cluster of 190 
measurements including 1) the first disproportionate increase in CO2 production (191 
co2) from visual inspection of individual plots of co2 vs. O2, 2) an increase in 192 
expired ventilation ( E) / O2 with no increase in E / co2, and 3) an increase in end-193 
tidal O2 tension with no fall in end-tidal CO2 tension.  The work rates that would 194 
require 90% of the GET (moderate-intensity exercise) and 70% Δ (GET plus 70% of 195 
the difference between the work rate at the GET and o2max; severe-intensity 196 
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exercise) were subsequently calculated with account taken of the mean response time 197 
for O2 during ramp exercise (i.e., two thirds of the ramp rate was deducted from the 198 
work rate at GET and peak).   199 
 200 
Familiarization Tests 201 
To avoid any order effect on the performance results as a consequence of a potential 202 
‘learning effect’, subjects were familiarized with all performance tests prior to the 203 
experimental testing.  Subjects completed a severe-intensity step exercise test 204 
terminating with an all-out sprint (exercise performance test) followed, after a 45 min 205 
passive recovery period, by a severe-intensity constant-work-rate step exercise test 206 
that was continued until the limit of tolerance (exercise tolerance test).   207 
 208 
Supplementation Procedures 209 
Experimental testing was conducted during a 7-day supplementation period with 210 
PLA, ARG and CIT.  The PLA supplement consisted of 10.7 g of maltodextrin; the 211 
ARG supplement consisted of 6 g L-arginine + 4.3 g of maltodextrin; and the CIT 212 
supplement consisted of 6 g L-citrulline + 4.3 g of maltodextrin.  All supplements 213 
were energy-matched containing 40 kcal per serving.  Pure maltodextrin,   L-arginine 214 
and L-citrulline powders were provided by NOW Sports Nutrition (NOW Foods, 215 
Bloomingdale, IL, USA) and were mixed with 500 mL water and 75 ml blackcurrant 216 
cordial in the proportions described above to produce the PLA, ARG and CIT 217 
supplements.  On days 1-5 of supplementation, subjects were instructed to drink the 218 
beverage slowly over the course of the day.  On days 6 and 7 of supplementation, 219 
subjects were instructed to consume the beverage over a 10 minute window such that 220 
the entire beverage had been consumed 60 min before the subject was required to 221 
report to the laboratory.   222 
 223 
Experimental Tests 224 
After reporting to the laboratory on days 6 and 7 of the supplementation interventions, 225 
subjects were required to rest in a seated position for 10 min in an isolated room. 226 
Thereafter, blood pressure of the brachial artery was measured whilst the subject was 227 
seated using an automated sphygmomanometer (Dinamap Pro, GE Medical Systems, 228 
Tampa, USA).  Four measurements were taken and the mean of the measurements 229 
was calculated.  A venous blood sample was then drawn into a lithium-heparin tube 230 
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and centrifuged at 4000 rpm and 4°C for 10 min, within 3 min of collection.  Plasma 231 
was subsequently extracted and immediately frozen at -80°C for later analysis of 232 
[NO2-] in duplicate via chemiluminescence (6) and [ARG], [CIT] and [L-ornithine] 233 
([ORN]) using high-performance liquid chromatography (HPLC; see below for 234 
details). 235 
 236 
Thirty minutes after arriving at the laboratory (90 minutes after the ingestion of the 237 
supplement), subjects completed a series of cycle exercise tests.  We elected to 238 
commence exercise testing 90 minutes after supplement consumption since published 239 
pharmacokinetic data has shown that this time frame should coincide with peak 240 
plasma [ARG] after orally ingesting 6 g CIT (53) or 6 g ARG (10).  The exercise 241 
protocol consisted of three ‘step’ exercise tests including two moderate-intensity step 242 
tests followed by one severe-intensity exercise bout.  Moderate-intensity step tests 243 
were completed to assess O2 kinetics and cycling economy in the absence of a O2 244 
slow component, while severe-intensity step tests were completed to assess O2 245 
kinetics in the presence of a O2 slow component where O2max is attained and the 246 
tolerable duration of exercise is <20 min  (49, 66).  We conducted repeated step tests 247 
on the same laboratory visit since a prior moderate-intensity step exercise bout does 248 
not impact on O2 kinetics during subsequent moderate- or severe-intensity cycle 249 
exercise (12, 16).   Therefore, all subjects performed a total of four bouts of moderate-250 
intensity exercise and two bouts of severe-intensity exercise for each experimental 251 
condition.   252 
 253 
Each transition began with 3 min of baseline cycling at 20 W before an abrupt 254 
transition to the target work rate.  A passive recovery of 5 min separated the 255 
transitions.  The moderate-intensity steps were each of 6 min duration.  On day 6 of 256 
each supplementation condition, subjects cycled for 6 min at a severe-intensity 257 
constant-work-rate (70% ∆) followed immediately by a 60 s all-out sprint.  The 258 
resistance on the pedals during the 60 s all-out effort was set using the linear mode of 259 
the Lode ergometer so that the subject would attain the power output calculated to be 260 
50% Δ if they attained their preferred cadence (linear factor = power/preferred 261 
cadence2).  Subjects were provided with a 5 s countdown prior to the sprint and were 262 
instructed to attain the peak power as quickly as possible and to continue exercising 263 
maximally for the duration of the sprint.  No time feedback was given to the subjects 264 
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at any point during the sprint.  On day 7 of the supplementation period, the severe-265 
intensity constant-work-rate bout was continued to the limit of tolerance.  The time to 266 
task failure was used as a measure of exercise tolerance and was recorded when the 267 
pedal rate fell by > 10 rpm below the required pedal rate. 268 
 269 
Measurements  270 
During all tests, pulmonary gas exchange and ventilation were measured breath-by-271 
breath with subjects wearing a nose clip and breathing through a low-dead-space, 272 
low-resistance mouthpiece and impeller turbine assembly (Jaeger Triple V).  The 273 
inspired and expired gas volume and gas concentration signals were continuously 274 
sampled at 100 Hz, the latter using paramagnetic (O2) and infrared (CO2) analyzers 275 
(Jaeger Oxycon Pro, Hoechberg, Germany) via a capillary line connected to the 276 
mouthpiece.  The gas analyzers were calibrated before each test with gases of known 277 
concentration and the turbine volume transducer was calibrated with a 3-liter syringe 278 
(Hans Rudolph, Kansas City, MO).  The volume and concentration signals were time-279 
aligned by accounting for the delay in the capillary gas transit and the analyzer rise 280 
time relative to the volume signal.  Pulmonary gas exchange and ventilation were 281 
calculated and displayed breath-by-breath.   282 
 283 
During the exercise trials, a blood sample was collected from a fingertip into a 284 
capillary tube over the 20 s preceding the step transition in work rate, the 20 s 285 
preceding the completion of 360 s of moderate and severe cycling exercise, and also 286 
immediately following the all-out sprint and immediately after exhaustion during the 287 
severe-intensity constant-work-rate trial.  These whole blood samples were 288 
subsequently analyzed to determine blood [lactate] (YSI 1500, Yellow Springs 289 
Instruments, Yellow Springs, OH, United States) within 30 s of collection. 290 
 291 
The oxygenation status of the m. vastus lateralis of the right leg was monitored using 292 
a commercially available near-infrared spectroscopy (NIRS) system (model NIRO 293 
300, Hamamatsu Photonics KK, Hiugashi-ku, Japan).  The system consisted of an 294 
emission probe that irradiates laser beams and a detection probe.  Four different 295 
wavelength laser diodes provided the light source (776, 826, 845, and 905 nm) and 296 
the light returning from the tissue was detected by a photomultiplier tube in the 297 
spectrometer.  The intensity of incident and transmitted light was recorded 298 
10 
 
continuously at 2 Hz and used to estimate concentration changes from the resting 299 
baseline for oxygenated, deoxygenated, and total tissue hemoglobin/myoglobin.  300 
Therefore, the NIRS data represent a relative change based on the optical density 301 
measured in the first datum collected.  The deoxygenated hemoglobin/myoglobin 302 
concentration ([HHb]) signal was assumed to provide an estimate of changes in 303 
fractional O2 extraction in the field of interrogation (e.g., 21).  It should be noted here 304 
that the contribution of deoxygenated myoglobin to the NIRS signal is presently 305 
unclear, and, as such, the terms [HbO2], and [HHb] used in this paper should be 306 
considered to refer to the combined concentrations of oxygenated and deoxygenated 307 
hemoglobin and myoglobin, respectively.  The tissue oxygenation index (TOI) was 308 
calculated using the following equation: 309 
 310 
TOI = ሾୌୠ୓మሿሾு௕ைమሿା ሾுு௕ሿ  × 100     (Eqn 1) 311 
 312 
The leg was initially cleaned and shaved around the belly of the muscle, and the 313 
optodes were placed in the holder, which was secured to the skin with adhesive at 20 314 
cm above the fibular head.  To secure the holder and wires in place, an elastic 315 
bandage was wrapped around the subject’s leg.  The wrap helped to minimize the 316 
possibility that extraneous light could influence the signal and also ensured that the 317 
optodes did not move during exercise.  Indelible pen marks were made around the 318 
holder to enable precise reproduction of the placement in subsequent tests.  The probe 319 
gain was set with the subject at rest in a seated position with the leg extended at down 320 
stroke on the cycle ergometer before the first exercise bout, and NIRS data were 321 
collected continuously throughout the exercise protocols.  The data were subsequently 322 
downloaded onto a personal computer, and the resulting text files were stored on disk 323 
for later analysis. 324 
 325 
Plasma [ARG], [CIT] and [ORN] were determined by o-phthaldialdehyde (OPA) 326 
derivatised, fluorescence-detection HPLC, using methods adapted from Jones and 327 
Gilligan (27). The HPLC apparatus was a Perkin Elmer Flexar LC system with 328 
Chromera software (Perkin Elmer, MASS, USA). In brief, plasma was de-proteinised 329 
in 1.5N perchloric acid, neutralised in 2N potassium hydrogen carbonate, and 330 
centrifuged. 100µL of supernatant, 100µL of 1.2% benzoic acid, and 1.4mL H2O 331 
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were added to HPLC vials. 50µL of unknowns/standards were mixed with 50µL of an 332 
OPA solution containing 2-mercaptoethanol (Fluoraldehyde OPA reagent solution, 333 
Thermo Scientific, IL, USA), enabling the pre-column derivatization of amino acids 334 
with a highly fluorescent OPA adduct. 25µL of derivatised sample was mixed in 335 
mobile phase and eluted at 0.8 ml.min-1 through a 4.6 x 150mm, 2.7 µm Brownlee 336 
SPP C18 reverse-phase analytical column with 5mm guard column with matching 337 
specification. A gradient protocol of aqueous mobile phase A (0.05M potassium 338 
phosphate buffer, pH 7.2) with organic mobile phase B (acetonitrile/methanol/water, 339 
40/40/20) was performed: 0 – 1.5 min, 80% Mobile A; 1.5 – 18.5, 80 – 65%; 23.5, 340 
50%; 32.5, 40%; 36.5, 30%; 43.5, 0%; 51.5, 80%. Fluorescence was monitored at 341 
excitation and emission wavelengths of 340 and 455 nm, respectively. Amino acid 342 
concentrations were determined against standards calibration curves between 0 and 343 
500 μM (nmol.mL-1). 344 
 345 
Data Analysis Procedures 346 
The breath-by-breath O2 data from each test were initially examined to exclude errant 347 
breaths caused by coughing, swallowing, sighing, etc., and those values lying more 348 
than four standard deviations from the local mean were removed.  The breath-by-349 
breath data were subsequently linearly interpolated to provide second-by-second 350 
values and, for each individual, identical repetitions were time-aligned to the start of 351 
exercise and ensemble-averaged.  The first 20 s of data after the onset of exercise (i.e., 352 
the phase I response) were deleted and a nonlinear least-square algorithm was used to 353 
fit the data thereafter.  A single-exponential model was used to characterize the O2 354 
responses to moderate exercise and a bi-exponential model was used for severe 355 
exercise, as described in the following equations:  356 
          357 
O2 (t) = O2 baseline + Ap(1-e- (t-TDp/τp))                                        (moderate)       (Eqn. 2) 358 
O2 (t) = O2 baseline + Ap(1-e- (t-TDp/τp)) + As(1-e- (t-TDs/τs))            (severe)       (Eqn. 3) 359 
 360 
where O2 (t) represents the absolute O2 at a given time t; O2baseline represents the 361 
mean O2 in the baseline period; Ap, TDp, and p represent the amplitude, time delay, 362 
and time constant, respectively, describing the phase II increase in O2 above baseline; 363 
and As, TDs, and s represent the amplitude of, time delay before the onset of, and 364 
time constant describing the development of, the O2 slow component, respectively.   365 
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An iterative process was used to minimize the sum of the squared errors between the 366 
fitted function and the observed values.  O2baseline was defined as the mean O2 367 
measured over the final 90 s of the resting baseline period.  The O2 at 360 s was taken 368 
as the mean O2 between 330 and 360 s, while the O2 at the limit of tolerance (Tlim) 369 
was defined as the mean O2 measured over the final 30 s of the exhaustive exercise 370 
bout.  Because the asymptotic value (As) of the exponential term describing the O2 371 
slow component may represent a higher value than is actually reached at the end of the 372 
exercise, the actual amplitude of the O2 slow component at the end of exercise was 373 
defined as As'.  The As' parameter was compared at the same iso-time (360-s) for all 374 
dietary interventions.  The amplitude of the slow component was also described 375 
relative to the entire O2 response.  In addition, the functional ‘gain’ (G) of the 376 
fundamental O2 response was computed by dividing Ap by the ∆ work rate.  To 377 
determine the overall kinetics of the O2 response to both moderate- and severe-378 
intensity exercise, the data were also fit with a mono-exponential model from 0-s to 379 
end-exercise without time delay.  This mean response time (MRT) was used to 380 
calculate the O2 deficit using the following equation:   381 
 382 
Oଶ Deficit ሺLሻ = MRTሺminሻ × Δ oଶ ሺLሻ                                   ሺEqn 4ሻ   
 383 
where Δ O2 was the difference in O2 at 360 s and baseline.  384 
 385 
To provide information on muscle oxygenation, we also modelled the [HHb] response 386 
to exercise. Mono- and bi-exponential models, similar to those described above, were 387 
applied to the ensemble averaged data with the exception that the fitting window 388 
commenced at the time at which the [HHb] signal increased 1 SD above the baseline 389 
mean.  The [HHb] kinetics for moderate exercise were determined by constraining the 390 
fitting window to the point at which mono-exponentiality became distorted, 391 
consequent to a gradual fall in [HHb], as determined by visual inspection of the 392 
residual plots.  The [HHb] kinetics for severe exercise were determined by fitting a bi-393 
exponential model from the first data point, which was 1 SD above the baseline mean 394 
through the entire response.  The [HHb] TD and τ values were summed to provide 395 
information on the overall [HHb] response dynamics in the fundamental phase of the 396 
response.  The [HbO2] response does not approximate an exponential and was, 397 
therefore, not modelled.  Rather, we assessed this by determining the [HbO2] at 398 
13 
 
baseline (90-s preceding step transition), 120 s (30 s mean surrounding 120 s) and end 399 
exercise (mean response over the final 30 s of exercise).  The TOI responses were 400 
assessed using the same data analysis procedures. 401 
 402 
Statistics 403 
A one-way repeated-measures ANOVA was employed to assess between-supplement 404 
differences in blood pressure; plasma [ARG], [CIT], [ORN] and [NO2-]; O2; NIRS-405 
derived [HHb], [HbO2] and TOI; and exercise performance.  Significant effects were 406 
further explored using simple contrasts with the alpha level adjusted via a Fisher’s 407 
LSD correction.  Data are presented as mean ± SD, unless otherwise stated.  Statistical 408 
significance was accepted when P<0.05.    409 
 410 
Results 411 
 412 
The PLA, ARG and CIT supplements administered in this study were well tolerated 413 
by all subjects with no negative side effects reported.  Subjects consumed all doses of 414 
the supplement for each experimental condition and their diet was consistent across 415 
all the dietary interventions.  The O2peak attained in the ramp incremental test was 416 
3.94 ± 0.51 L·min-1 which equated to a relative O2peak of 50 ± 9 ml·kg-1·min-1.  The 417 
work rates which corresponded to 90% GET and 70% Δ were 120 ± 23 W and 284 ± 418 
40 W, respectively.   419 
 420 
Plasma [NO2-], [ARG], [CIT] and [ORN]  421 
The plasma [NO2-], [ARG], [CIT] and [ORN] data for the PLA, ARG and CIT 422 
conditions are reported in Table 1.  The ANOVA revealed a significant main effect 423 
for supplement on plasma [ARG], [CIT] and [ORN] (all P<0.001).  Plasma [ARG] 424 
was increased above PLA (57 ± 14 μM) in ARG (151 ± 31 μM) and CIT (135 ± 22 425 
μM; both P<0.001), with no differences between ARG and CIT (P>0.05; Table 1).  426 
Plasma [CIT] was not significantly different between PLA (23 ± 5 μM) and ARG (26 427 
± 6 μM; P>0.05), but was significantly greater that both these conditions with CIT 428 
(665 ± 205 μM; P<0.001; Table 1).  Plasma [ORN] was significantly greater in CIT 429 
(50 ± 6 μM) than PLA (26 ± 8 μM; P<0.001) and significantly greater in ARG (62 ± 430 
14) than both PLA and CIT (P>0.05; Table 1).   Plasma [NO2-] was significantly 431 
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increased in ARG (106 ± 41 nM; P<0.05), but not following CIT supplementation 432 
(100 ± 38 nM; P=0.08), compared to PLA (83 ± 25 nM; Table 1).   433 
 434 
Blood Pressure 435 
The blood pressure data for the PLA, ARG and CIT conditions are reported in Table 436 
2. There was a significant main effect for supplement on systolic blood pressure 437 
(SBP; P<0.05), with follow up analyses showing that SBP was lower after CIT (118 ± 438 
6 mmHg; P<0.05), but not after ARG (120 ± 7 mmHg; P>0.05), compared to PLA 439 
(122 ± 7 mmHg; Table 2).  While there was no main effect for supplement on 440 
diastolic blood pressure (DBP; P>0.05), there was a significant main effect for 441 
supplement on mean arterial pressure (MAP; P<0.05).  Relative to PLA (87 ± 3 442 
mmHg), MAP was lower after CIT (85 ± 2 mmHg; P<0.05), but not ARG (86 ± 2 443 
mmHg; P>0.05; Table 2).        444 
 445 
Pulmonary O2 Kinetics 446 
The pulmonary gas exchange data from the moderate- and severe-intensity cycle tests 447 
are reported in Table 3.  There were no significant between-supplement differences 448 
for the baseline and end-exercise O2 during the moderate-intensity step exercise tests 449 
(P>0.05).  Accordingly, the fundamental O2 amplitude was not significantly 450 
different between the conditions (PLA: 0.87 ± 0.21, ARG: 0.87 ± 0.22, CIT: 0.86 ± 451 
0.23 L·min-1; P>0.05; Table 3).  The phase II τ was also not significantly different 452 
between conditions (PLA: 24 ± 7, ARG: 22 ± 7, CIT: 21 ± 6 s; P>0.05; Table 3). 453 
 454 
The baseline O2 and phase II O2 kinetics during severe-intensity exercise were not 455 
significantly impacted by the dietary interventions employed in this investigation 456 
(P>0.05 for all comparisons).  The O2 at exhaustion was not significantly different 457 
between experimental conditions and was also not significantly different from the 458 
O2peak attained in the ramp incremental test (P>0.05 for all comparisons).  No 459 
significant differences in the fundamental O2 amplitude (PLA: 2.23 ± 0.34, ARG: 460 
2.26 ± 0.42, CIT: 2.29 ± 0.45 L·min-1) or O2 slow component (PLA: 0.66 ± 0.09, 461 
ARG: 0.60 ± 0.12, CIT: 0.58 ± 0.13 L·min-1; P>0.05; Table 3) were observed across 462 
the experimental conditions.  However, there was a significant main effect for 463 
supplement on the MRT (P<0.05), with faster overall O2 kinetics observed after CIT 464 
compared to PLA supplementation (PLA: 60 ± 8, CIT: 54 ± 5 s; P<0.05; Figure 1).  465 
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There were no significant differences in cO2 and RER between the PLA, ARG and 466 
CIT conditions during moderate- or severe-intensity cycle exercise (P>0.05 for all 467 
comparisons, data not shown).  There were also no between condition differences in 468 
blood [lactate] at any time comparison in this study (P>0.05, data not shown).     469 
 470 
NIRS Variables 471 
The NIRS-derived muscle [HHb], [HbO2] and TOI data during moderate- and severe-472 
intensity cycle exercise with PLA, ARG and CIT supplementation are reported in 473 
Table 4.  There were no significant differences between the experimental conditions 474 
for the [HbO2] and TOI responses during moderate-intensity exercise (P>0.05 for all 475 
comparisons).  However, the [HHb] amplitude during moderate-intensity cycling 476 
exercise was significantly lower after CIT supplementation (PLA: 8 ± 4, CIT: 6 ± 4 477 
A.U.; P>0.05; Figure 2).  While there were no significant between-supplement 478 
differences in [HHb] dynamics or in muscle [HbO2] during severe-intensity cycle 479 
exercise in this study, the muscle TOI was significantly elevated over the first 360 s of 480 
severe-intensity exercise with CIT supplementation (P<0.05; Table 4; Figure 3).      481 
 482 
Exercise Performance 483 
The power profiles for the three experimental conditions during the 60 s all-out sprint 484 
that followed the 6 min bout of severe-intensity exercise (the exercise performance 485 
test) are shown in Figure 4, while the times to exhaustion during the severe-intensity 486 
constant-work-rate cycle trials (the exercise tolerance test) are shown in Figure 5.  A 487 
significant main effect for supplement was observed for the peak power attained and 488 
total work completed during the 60 s all-out sprint that concluded the exercise 489 
performance test (P<0.05).  Follow up analyses showed that, compared to PLA, CIT 490 
supplementation increased the test peak power by 9% (PLA: 480 ± 98, CIT: 524 ± 94 491 
W; P<0.05; Figure 4) and the total work completed during the 60 s sprint by 7% 492 
(PLA: 21 ± 4, CIT: 23 ± 4 kJ; P<0.05; Figure 4).  Neither peak power output (482 ± 493 
102 W) nor total sprint work completed (21 ± 5 kJ) were significantly impacted by 494 
ARG supplementation (P>0.05).  The total work completed over the entire exercise 495 
performance test was greater with CIT (125 ± 19 kJ; P<0.05), but not ARG (124 ± 19 496 
kJ; P>0.05), compared to PLA (123 ± 18 kJ; P<0.05).  There was a strong trend for a 497 
main effect of supplement on the time-to-exhaustion during the exercise tolerance test 498 
(P=0.07).  When between-condition analyses were conducted, there was a significant 499 
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12% increase in exercise tolerance time after CIT supplementation relative to PLA 500 
(PLA: 589 ± 101, CIT: 661 ± 107 s; P<0.05; Figure 5).  Exercise tolerance was not 501 
significantly improved with ARG (612 ± 150 s) compared to PLA (P>0.05).  The 502 
changes in exercise tolerance after CIT supplementation were not related to changes 503 
in plasma [NO2-], O2 kinetics or muscle oxygenation (P>0.05 for all comparisons).       504 
 505 
Discussion 506 
 507 
The principal novel findings from this study are that short-term supplementation with 508 
pure CIT enhanced endurance exercise performance in concert with faster overall O2 509 
kinetics and a 21% increase in the sensitive NO biomarker, plasma [NO2-].  This is in 510 
contrast to previous research demonstrating that acute CIT supplementation lowers 511 
plasma [NOx] and compromises exercise tolerance (26), but consistent with studies 512 
showing that short term supplementation with L-citrulline malate can positively 513 
impact on skeletal muscle power output and metabolic responses (7, 19).  These 514 
findings are important since they suggest that CIT might be responsible for the 515 
positive effects previously reported following L-citrulline malate supplementation, and 516 
offer new insights into the mechanisms by which CIT supplementation might be 517 
ergogenic.  Conversely, no significant differences in O2 kinetics and exercise 518 
performance were observed following short-term ARG supplementation.  These 519 
findings suggest that short-term CIT supplementation, but not short term ARG 520 
supplementation, might be an effective dietary intervention to improve oxidative 521 
metabolism and exercise performance in healthy adults.         522 
 523 
Influence of ARG and CIT supplementation on plasma [ARG], [CIT] and [NO2-]  524 
In an attempt to overcome the well developed inter-organ system for ARG clearance, 525 
recent studies have investigated the efficacy of oral CIT supplementation as an 526 
alternative method to enhance NO production via NOS.  Oral CIT supplementation is 527 
appealing in this regard since CIT is not significantly metabolized in the gut (68) and 528 
liver (59, 65), and less than 1% of orally ingested CIT is excreted in the urine (50).  529 
As such the majority of an oral CIT load passes into the systemic circulation, as 530 
reflected by a significant increase in plasma [CIT] after CIT ingestion in the current 531 
study and numerous previous reports (8, 16, 42, 51, 53).  Thereafter the bulk of 532 
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plasma CIT is converted into ARG, mostly in the kidneys (15, 24, 59, 65, 70), but also 533 
in several other tissues (15, 23, 70).  This is compatible with the significant increase 534 
in plasma [ARG] in this study, and several previous studies (32, 47, 53, 62), following 535 
CIT supplementation.  It is important to note that, not only does CIT increase 536 
systemic [ARG] by avoiding catabolism along the intestinal-renal axis, but CIT might 537 
also be expected to enhance ARG bioavailability given that CIT can function as an 538 
allosteric inhibitor of arginase (54).  This is supported by our finding of a lower 539 
plasma [ORN], the product of ARG metabolism by arginase (70), after CIT compared 540 
to ARG supplementation in this study.  However, in spite of this potential for greater 541 
systemic ARG bioavailability following oral CIT compared to oral ARG 542 
supplementation, and in contrast to previous studies reporting a greater increase in 543 
plasma [ARG] after CIT ingestion relative to ARG ingestion (32, 47, 53, 62), plasma 544 
[ARG] was increased by a similar magnitude when the same dose of CIT and ARG 545 
was orally administered in this study.  These conflicting findings might be a function 546 
of between-study differences in the experimental subjects and supplementation 547 
regimes.  Therefore, our results do not support the notion of a greater systemic ARG 548 
availability after CIT compared to ARG supplementation, at least in healthy adult 549 
males undergoing the ARG and CIT supplementation procedures employed in this 550 
study.   551 
 552 
As well as increasing NOS substrate provision, there is some evidence to suggest that 553 
NO production is enhanced after CIT treatment (46, 53, 63) and that CIT can restore 554 
NO production in conditions where NO production is compromised (16, 36).  555 
However, there is also a suggestion that CIT ingestion tends to lower NO production, 556 
as inferred from plasma [NOx] (26).  Plasma [NO2-] better reflects human NOS 557 
activity than plasma [NOx] (34) and is likely to provide a more accurate assessment 558 
of NOS-derived NO.  In this study CIT supplementation increased plasma [NO2-] by 559 
21%, but this increase did not attain statistical significance (P=0.08).  On the other 560 
hand, ARG supplementation resulted in a statistically significant (28%) increase in 561 
plasma [NO2-].  Taken together, these data suggest that short-term ARG 562 
supplementation might be more effective than CIT supplementation at increasing the 563 
sensitive biomarker of NOS activity, plasma [NO2-] (28, 34). However, the extent to 564 
which plasma [NO2-] reflects skeletal muscle NOS activity is unclear.  In this study 565 
plasma [ORN] was lower following CIT than ARG.  It is known that ORN competes 566 
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with ARG for cellular uptake via the y+ carrier system (70).  As such, this might have 567 
facilitated greater skeletal muscle ARG uptake after CIT compared to ARG 568 
supplementation in this study. The finding of a greater increase in tissue [ARG] (63) 569 
after CIT ingestion relative to ARG ingestion supports this postulate.  Moreover, the 570 
lower plasma [ORN] following CIT than ARG, despite a similar increase in plasma 571 
[ARG], implies a lower arginase activity following CIT (70).  Providing muscle 572 
[ORN] was also lower following CIT compared to ARG supplementation in this 573 
study, muscle arginase activity may have been downregulated.  While there appears to 574 
be some controversy regarding the levels of arginase in human skeletal muscle (20, 575 
45), the potential for CIT to inhibit arginase might be important since arginase-II 576 
content in human skeletal muscle can be similar to that observed in the kidney, i.e., 577 
relatively high (45).  Therefore, the functional effects of CIT (described below) may 578 
be muscle-specific and not detected as changes in plasma [NO2-], which may be more 579 
indicative of gross changes in NOS activity throughout the body. Likewise, the ARG-580 
induced increase in plasma [NO2-], observed in the present study, may be due to non-581 
endothelial NOS-mediated NO production or NOS-mediated NO production at sites 582 
other than skeletal muscle. 583 
 584 
Influence of ARG and CIT supplementation on blood pressure 585 
A hallmark of enhanced NO synthesis is a reduction in blood pressure owing to NO-586 
induced smooth muscle relaxation (22). It has also recently been demonstrated that 587 
circulating NO2- itself can act as a source for NO synthesis via endogenous human 588 
nitrite reductase activities, associated with proteins such as xanthine oxidase and 589 
deoxyhemoglobin (see 37 for review).  However, in spite of a significant increase in 590 
plasma [NO2-] after ARG supplementation, resting blood pressure was not 591 
significantly lowered.  This suggests that the increase in plasma [NO2-] after short-592 
term ARG supplementation might not have been sufficient to lower resting blood 593 
pressure in normotensive adults.  Conversely, CIT supplementation, which did not 594 
significantly increase plasma [NO2-], significantly reduced resting blood pressure.  595 
Although previous studies have shown a reduction in arterial stiffness (46), enhanced 596 
endothelium-dependent vasorelaxation in response to acetylcholine (25) and an 597 
association between the change in the ARG/ADMA ratio and flow mediated dilation 598 
(53) with CIT, we have shown for the first time that pure CIT supplementation can 599 
reduce blood pressure in healthy normotensive adults.  An increase in cyclic 600 
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guanosine monophosphate (cGMP) has been reported after short-term CIT 601 
consumption (49) which suggests that the reduction in blood pressure with CIT might 602 
result from NO-cGMP-related smooth muscle relaxation.  Alternatively, CIT might 603 
alter vascular tone through another endothelium-derived relaxing factor such as 604 
prostacyclin or endothelium-derived hyperpolarizing factors independent of, or 605 
alongside, an increase in NO.  Further research is required to investigate the 606 
mechanisms by which CIT might positively impact on vascular and other 607 
physiological responses.     608 
 609 
Influence of ARG and CIT supplementation on O2 kinetics  610 
Giannesini et al. (19) reported that short-term L-citrulline malate supplementation 611 
lowered both the oxidative and phosphocreatine cost of skeletal muscle force 612 
production in the rat gastrocnemius muscle in situ.  We have previously shown that 613 
short-term dietary nitrate supplementation can also lower skeletal muscle ATP 614 
turnover by attenuating ATP flux through oxidative phosphorylation and 615 
phosphocreatine (PCr) hydrolysis in association with lower O2 in humans 616 
completing knee-extensor exercise (2).  Therefore, we hypothesized that short term 617 
CIT supplementation might lower O2 in humans completing cycle exercise.  618 
However, in contrast to our previous findings with dietary nitrate supplementation (6) 619 
and our experimental hypothesis, short term CIT supplementation did not 620 
significantly lower O2 during moderate-intensity cycle ergometry exercise.  Our 621 
findings in this study might differ with those reported by Giannesinin et al. (19) as a 622 
consequence of differences in the experimental model (human skeletal muscle 623 
contraction in vivo vs. isolated rat skeletal muscle in situ) or differences in the L-624 
citrulline supplementation procedures (pure L-citrulline supplementation vs. L-625 
citrulline malate supplementation).   626 
 627 
In the present study short term CIT supplementation did not significantly increase 628 
plasma [NO2-] and moderate exercise O2 was not significantly altered.  We have 629 
recently shown that acute ARG ingestion did not increase plasma [NO2-] or lower 630 
moderate exercise O2 (60).  However, plasma [NO2-] was increased by 28% 631 
following short term ARG in the present study without impacting on moderate 632 
exercise O2.  Importantly neither ARG nor CIT increased plasma [NO2-] to the extent 633 
observed when moderate exercise O2 is lowered by dietary nitrate supplementation 634 
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(2, 5-6, 33) and this likely accounts for the similar moderate exercise O2 across PLA, 635 
ARG and CIT in the present study.  While neither the steady-state O2 nor the rate at 636 
which O2 increased following the onset of moderate-intensity exercise were 637 
significantly impacted by ARG or CIT supplementation, the NIRS-derived muscle 638 
[HHb] amplitude was lower with CIT.  Since the NIRS-derived muscle [HHb] signal 639 
is considered a non-invasive proxy for muscle fractional O2 extraction (e.g., 21), the 640 
lower muscle [HHb] amplitude with CIT in the absence of a change in O2 suggests 641 
that CIT may have improved O2 availability/distribution within the muscle 642 
microvasculature.                 643 
 644 
During severe-intensity exercise, the overall O2 kinetics was faster following CIT 645 
supplementation compared to PLA.  These data support the findings of Bendahan et 646 
al. (7) who reported that L-citrulline malate supplementation elevated muscle 647 
oxidative ATP production determined in vivo using 31P-MRS.  The faster overall O2 648 
kinetics after CIT supplementation was accompanied by an increased NIRS-derived 649 
TOI throughout the exercise bout.  This suggests that CIT supplementation improved 650 
the distribution of O2 within the muscle microvasculature which, in turn, permitted a 651 
greater O2 over the initial stages of severe-intensity cycle exercise.  Previous studies 652 
have also reported that overall O2 kinetics during severe-intensity exercise is speeded 653 
by interventions that enhance muscle O2 availability (e.g., 3, 64).  However, it is 654 
known that muscle NIRS measures manifest significant special heterogeneities across 655 
the contracting quadriceps (29) so it is unclear whether a lower [HHb] amplitude 656 
during moderate-intensity exercise, and the increased TOI during severe-intensity 657 
exercise, at a discrete site of the vastus lateralis is reflective of an improved matching 658 
between muscle O2 delivery and muscle O2 consumption across the contracting 659 
quadriceps.  Indeed, some studies report good agreement between NIRS markers of 660 
muscle oxygenation and mixed venous PO2 or oxygenation (e.g., 39), while other 661 
studies do not (e.g., 38).  It has also been suggested that the interpretation of NIRS 662 
data may be complicated by increased skin blood flow (30, 40), as develops during 663 
exercise.  However, the NIRS-derived [HHb] (30) and TOI (40) that were used to 664 
draw inferences on muscle oxygenation in this study are not altered by increased skin 665 
blood flow.  Alternatively, since short-term L-citrulline malate supplementation has 666 
been shown to speed the rate of muscle phosphocreatine resynthesis following 667 
exercise (7, 18), a process coupled to the maximal rate of ATP derived from 668 
21 
 
mitochondrial oxidative phosphorylation (41), it is also possible that CIT speeded 669 
overall O2 kinetics through enhancing muscle oxidative metabolism independent of 670 
enhanced muscle O2 delivery.  There was no improvement in NIRS-derived TOI or 671 
O2 dynamics during severe exercise in this study after ARG supplementation.  672 
 673 
Influence of ARG and CIT supplementation on exercise performance 674 
Severe exercise tolerance was increased by 12% and subjects completed 7% more 675 
sprint work during an exercise performance test with CIT supplementation.  While L-676 
citrulline malate supplementation has been shown to increase muscle force production 677 
(7, 19), to improve muscle contractile efficiency (19) and to prevent the decline in 678 
muscle force production with endotoxemia (18), studies investigating the effects of 679 
CIT on exercise performance or muscle fatigue resistance are limited and equivocal.  680 
Of the two studies investigating the influence of CIT supplementation on exercise 681 
performance to date, one has reported improved exercise tolerance in mice performing 682 
swimming exercise (56), while the other showed that CIT compromised incremental 683 
exercise performance in humans (26).  It is unclear why our findings contrast with 684 
those of Hickner et al. (26).  While Hickner et al. (26) designed an experiment to 685 
assess the influence of acute ingestion of either 3 or 9 g of CIT on incremental 686 
treadmill exercise performance, we investigated the effects of 7 days of 6 g·day-1 687 
supplementation with CIT on cycling exercise tolerance and performance.  These 688 
conflicting findings might therefore be a consequence of different exercise 689 
performance tests and dosing procedures, with 6-7 days of supplementation being 690 
more effective than acute CIT ingestion.  Moreover, an important difference between 691 
these studies is the influence of CIT supplementation on NO biomarkers.  692 
Specifically, we have shown that short term CIT tended (P=0.08) to increase plasma 693 
[NO2-] and improved exercise performance, whereas Hickner et al. (26) reported a 694 
surprising tendency for acute CIT to lower plasma [NOx] (plasma [nitrite] + [nitrate]) 695 
and to compromise exercise performance.  Therefore, the extent to which CIT 696 
influences exercise performance appears to be linked to the duration of the 697 
supplementation period and its impact on NO bioavailability.        698 
 699 
The improved exercise performance after CIT supplementation was accompanied by 700 
faster overall O2 kinetics although there was no significant correlation between the 701 
two.  An increase in muscle oxidative ATP turnover in concert with a lower pH/power 702 
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ratio after L-citrulline malate supplementation has also been reported previously (7).  703 
While we observed no change in blood [lactate] during and after severe-intensity 704 
exercise with CIT supplementation in this study, previous studies have reported lower 705 
end-exercise blood [lactate] and [ammonia] (56), as well as a lower rate of muscle 706 
phosphocreatine degradation (19) with CIT.  Taken together, these findings suggest 707 
that CIT supplementation might increase the proportional energy contribution from 708 
oxidative metabolism thereby limiting the utilization of the finite anaerobic energy 709 
reserves and reducing the accumulation of metabolites linked to the process of muscle 710 
fatigue.   711 
 712 
The findings presented in this study suggest that short-term supplementation with L-713 
citrulline powder might lower blood pressure, speed O2 kinetics and improve 714 
exercise tolerance/performance.  An alternative, natural, method to increase dietary L-715 
citrulline intake is via the consumption of watermelon (Citrullus lanatus), which 716 
contains ~2.33 g of L-citrulline/L of unpasteurized watermelon juice (58).  717 
Accordingly, subjects would be required to consume a daily watermelon dose of ~2.5 718 
L in order to ingest the same dose of L-citrulline administered in this study.  Further 719 
research is required to determine whether the effects reported following short term 720 
CIT supplementation in this study can be reproduced using watermelon juice 721 
supplementation.        722 
 723 
In conclusion, this study has shown that short-term CIT supplementation can reduce 724 
blood pressure, speed O2 kinetics and enhance endurance exercise performance.  725 
Supplementation with ARG, on the other hand, did not significantly impact on these 726 
parameters.  Therefore, the results of this study suggest that chronic supplementation 727 
with CIT might represent a practical, dietary intervention to reduce blood pressure, 728 
and enhance oxidative metabolism and exercise performance in young, healthy adults.  729 
 730 
 731 
 732 
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Figure Legends 995 
 996 
Figure 1: The pulmonary O2 mean response time (MRT) during severe-intensity 997 
constant-work-rate cycle exercise after placebo (PLA), L-arginine (ARG) and L-998 
citrulline (CIT) supplementation. The upper panel compares the O2 MRT following 999 
placebo (PLA) and L-arginine (ARG) supplementation.  The lower panel compares 1000 
the O2 MRT following following PLA and L-citrulline (CIT) supplementation.  The 1001 
filled bars represent the group mean ± SEM responses after ARG and CIT 1002 
supplementation, while the open bars represent the group mean ± SEM responses 1003 
after PLA supplementation.  The solid grey lines represent the individual responses to 1004 
the supplements. * indicates significantly different from PLA (P<0.05).  Note the 1005 
significant decrease in the O2 MRT after CIT but not ARG supplementation. 1006 
 1007 
Figure 2: Group mean NIRS-derived muscle [deoxyhemoglobin] ([HHb]) during a 1008 
moderate-intensity step cycle test following placebo (PLA), L-arginine (ARG) and L-1009 
citrulline (CIT) supplementation.  Note the significant reduction in the [HHb] 1010 
amplitude during moderate-intensity cycling exercise after CIT, but not ARG 1011 
supplementation, compared to PLA. 1012 
 1013 
Figure 3: Group mean NIRS-derived muscle tissue oxygenation index (TOI) during a 1014 
severe-intensity step cycle test following placebo (PLA), L-arginine (ARG) and L-1015 
citrulline (CIT) supplementation.  Note the significant increase in muscle oxygenation 1016 
during severe-intensity cycling exercise after CIT, but not ARG supplementation, 1017 
compared to PLA. 1018 
 1019 
Figure 4: Group mean power profiles during a 60 s all-out cycle sprint commenced 1020 
immediately after 6 min of severe-intensity cycle exercise following placebo (PLA), 1021 
L-arginine (ARG) and L-citrulline (CIT) supplementation. Note the significant 1022 
increase in peak and mean power output during the 60 s all-out sprint after CIT, but 1023 
not ARG supplementation, compared to PLA. 1024 
 1025 
Figure 5: Time-to-exhaustion during severe-intensity constant-work-rate cycle 1026 
exercise after placebo (PLA), L-arginine (ARG) and L-citrulline (CIT) 1027 
supplementation. The upper panel compares time-to-exhaustion following placebo 1028 
34 
 
(PLA) and L-arginine (ARG) supplementation.  The lower panel compares time-to-1029 
exhaustion following PLA and L-citrulline (CIT) supplementation.  The filled bars 1030 
represent the group mean ± SEM responses after ARG and CIT supplementation, 1031 
while the open bars represent the group mean ± SEM responses after PLA 1032 
supplementation.  The solid grey lines represent the individual responses to the 1033 
supplements. * indicates significantly different from PLA (P<0.05).  Note the 1034 
significant increase in exercise tolerance after CIT but not ARG supplementation. 1035 
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Table 1. Resting plasma [nitrite] and blood pressure measures following placebo 1074 
(PLA), L-arginine (ARG) and L-citrulline (CIT) supplementation. 1075 
 1076 
 PLA ARG CIT 
    
Plasma [nitrite] (nM) 83 ± 25 106 ± 41* 100 ± 38 
Plasma [L-arginine] (μM) 57 ± 14 151 ± 31* 135 ± 22* 
Plasma [L-citrulline] (μM) 23 ± 5 26 ± 6 665 ± 205*# 
Plasma [L-ornithine] (μM) 26 ± 8 62 ± 14* 50 ± 6*# 
    
Values are presented as the mean ± SD. * = significantly different from placebo 1077 
(P<0.05); # = significantly different from ARG (P<0.05). 1078 
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Table 2. Resting blood pressure measures following placebo (PLA), L-arginine 1116 
(ARG) and L-citrulline (CIT) supplementation. 1117 
 1118 
 PLA ARG CIT 
    
Systolic blood pressure (mmHg) 122 ± 7 121 ± 5 118 ± 6* 
Diastolic blood pressure (mmHg) 65 ± 6 63 ± 4 64 ± 5 
Mean arterial pressure (mmHg) 87 ± 3 86 ± 2 85 ± 2* 
    
Values are presented as the mean ± SD. * = significantly different from placebo 1119 
(P<0.05). 1120 
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Table 3. Pulmonary gas exchange measures during moderate- and severe-1160 
intensity cycle exercise after placebo (PLA), L-arginine (ARG) and L-citrulline 1161 
(CIT) supplementation. 1162 
 1163 
 PLA ARG CIT 
    
Moderate-intensity exercise 
    
Oxygen Uptake ( O2)  
Baseline (L∙min-1) 1.07 ± 0.83 1.09 ± 0.11 1.09 ± 0.13 
End-exercise (L∙min-1) 1.94 ± 0.29 1.96 ± 0.28 1.93 ± 0.30 
Phase II time constant (s) 24 ± 7 22 ± 7 21 ± 6 
Mean response time (s) 37 ± 7 38 ± 7 36 ± 6 
Fundamental amplitude (L∙min-1) 0.87 ± 0.21 0.87 ± 0.22 0.86 ± 0.23 
Fundamental gain (ml∙min-1·W-1) 8.7 ± 0.5 8.7 ± 0.6 8.7 ± 0.7 
Oxygen deficit (L) 0.54 ± 0.16 0.55 ± 0.16 0.51 ± 0.15 
    
Severe-intensity exercise 
    
Oxygen Uptake ( O2)    
Baseline (L∙min-1) 1.12 ± 0.10 1.13 ± 0.13 1.13 ± 0.11 
360 s (L∙min-1) 3.94 ± 0.49 3.95 ± 0.49 3.94 ± 0.51 
Exhaustion (L∙min-1)  4.12 ± 0.50 4.09 ± 0.49 4.13 ± 0.56 
Phase II time Constant (s) 26 ± 7 26 ± 6 25 ± 6 
Fundamental amplitude (L∙min-1) 2.23 ± 0.34 2.26 ± 0.42 2.29 ± 0.45 
Slow component amplitude (L∙min-1) 0.66 ± 0.09 0.60 ± 0.12 0.58 ± 0.13 
Slow component amplitude (%) 23 ± 2 21 ± 4 20 ± 5 
Overall mean response time (s) 60 ± 8 56 ± 7 54 ± 5* 
Values are presented as the mean ± SD. * = significantly different from placebo 1164 
(P<0.05). 1165 
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Table 4. Near-infrared spectroscopy measures during moderate- and severe-1184 
intensity cycle exercise after placebo (PLA), L-arginine (ARG) and L-citrulline 1185 
(CIT) supplementation. 1186 
 1187 
Values are presented as the mean ± SD. * = significantly different from placebo 1188 
(P<0.05). 1189 
 1190 
 PLA ARG CIT 
    
Moderate-intensity exercise 
    
Muscle [HHb]    
Baseline [HHb] (A.U) -3 ± 5 -2 ± 4 -5 ± 4 
120 s (A.U) 4 ± 7 5 ± 7 1 ± 5 
End-exercise [HHb] (A.U) 4 ± 8 7 ± 6 1 ± 6 
[HHb] τ (s) 11 ± 2 10 ± 3 9 ± 5 
[HHb] τ + TD (s) 19 ± 3 18 ± 3 19 ± 4 
[HHb] amplitude (A.U) 8 ± 4 9 ± 7 6 ± 4* 
    
Muscle [HbO2]    
Baseline [HbO2] (A.U) 5 ± 2 4 ± 3 4 ± 4 
120 s (A.U) 3 ± 2 0 ± 3 2 ± 3
End-exercise [HbO2] (A.U) 5 ± 2 3 ± 4 4 ± 4 
    
Tissue oxygenation index    
Baseline TOI (%) 67 ± 2 67 ± 2 69 ± 7 
120 s (%) 60 ± 5 59 ± 7 63 ± 10 
End-exercise TOI (%) 61 ± 6 59 ± 7 64 ± 11 
    
Severe-intensity exercise
    
Muscle [HHb]    
Baseline [HHb] (A.U) -6 ± 5 -3 ± 4 -7 ± 4 
120 s (A.U) 15 ± 13 16 ± 11 10 ± 8 
End-exercise [HHb] (A.U) 16 ± 12 18 ± 11 12 ± 9 
[HHb] primary τ (s) 8 ± 2 9 ± 2 9 ± 2 
[HHb] primary τ + TD (s) 10 ± 2 11 ± 2 11 ± 2 
[HHb] primary amplitude (A.U) 19 ± 10 19 ± 12 16 ± 9 
[HHb] slow-phase amplitude (A.U) 3 ± 1 3 ± 2 3 ± 2 
    
Muscle [HbO2]    
Baseline [HbO2] (A.U) 12 ± 3 10 ± 5 10 ± 5 
120 s (A.U) -6 ± 8 -8 ± 8 -5 ± 4 
End-exercise [HbO2] (A.U) -10 ± 9 -11 ± 9 -8 ± 5 
    
Tissue oxygenation index    
Baseline TOI (%) 72 ± 3 71 ± 3 75 ± 8 
120 s (%) 47 ± 12 46 ± 12 52 ± 13* 
End-exercise TOI (%) 43 ± 12 43 ± 12 49 ± 13* 
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